CJC-1295

What it is

CJC-1295 (no DAC), also known as Modified GRF 1-29, is a synthetic 30-amino-acid GHRH analog with four amino acid substitutions from native GHRH that confer enhanced stability and binding affinity. The “no DAC” designation distinguishes it from CJC-1295 with DAC (Drug Affinity Complex), which has an additional lysine-maleimidopropionic acid modification that binds albumin and dramatically extends half-life — a property that is sometimes desired but, in our view, removes one of the main physiologic safety features of pulsatile GH release.

The four substitutions in CJC-1295 (no DAC) — D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27 — protect against DPP-4 cleavage and other proteolytic degradation pathways. The result is a peptide with the pharmacological behavior of native GHRH but with a moderately extended half-life (~30 minutes vs. ~7 minutes for native GHRH), preserving pulsatility while providing stronger and more consistent GH responses.

CJC-1295 (no DAC) is not FDA-approved for any indication. It is available through licensed compounding pharmacies and has accumulated significant clinical use in the GH-axis support space, particularly when paired with ipamorelin.

Mechanism of action

The mechanism is the same as sermorelin and tesamorelin: binding of the pituitary GHRH receptor and stimulation of endogenous, pulsatile GH release. The differences are pharmacokinetic:

• Half-life of ~30 minutes vs. ~10–20 minutes for sermorelin — long enough to provide sustained signaling at the pituitary, short enough to preserve pulsatile release patterns
• Higher binding affinity for the GHRH receptor than native GHRH
• More stable to enzymatic degradation, allowing more consistent dosing-to-effect relationships

The pulsatile nature of GH release is a critical safety feature. Continuous high GH levels (as can occur with CJC-1295 with DAC, or with exogenous recombinant GH dosed inappropriately) are associated with the metabolic and physical features of acromegaly — soft tissue overgrowth, joint problems, insulin resistance, and possibly increased cardiovascular and malignancy risk over time. Pulsatile GH, in contrast, is the natural pattern and appears to support beneficial effects without these costs.

Research findings

The original CJC-1295 (with DAC) was studied in early-phase clinical trials by ConjuChem in the early 2000s. The clinical development program was eventually discontinued, partly due to concerns about a serious adverse event (heart attack) in one trial participant — though this was not definitively linked to the drug. Importantly, much of the published “CJC-1295” data refers to the DAC version, not the no-DAC version we prescribe.

Specific clinical trial data on CJC-1295 (no DAC) is more limited. The pharmacology is well-characterized in terms of GH and IGF-1 responses, with documented improvements over native GHRH and sermorelin in terms of dose-response and reliability. Most clinical evidence supporting CJC-1295 (no DAC) use comes from practitioner experience and the broader literature on combined GHRH + GHRP signaling.

The combination of CJC-1295 (no DAC) with ipamorelin is the most common clinical application. The two peptides act synergistically — GHRH analogs and GHRPs (like ipamorelin) work through complementary pathways at the pituitary, and combined administration produces GH release that is greater than either alone.

How we use it at The Tide

CJC-1295 (no DAC) + ipamorelin is one of our most frequently prescribed combinations for adult patients with documented age-related GH axis decline who have appropriate clinical indications.

Standard protocol:

• CJC-1295 (no DAC) 100 mcg + ipamorelin 200 mcg, combined in a single subcutaneous injection
• Administered 5 nights per week at bedtime
• 12-week cycles followed by 4–6 week breaks
• Monitoring with IGF-1 at baseline and 90 days; CMP and fasting glucose at the same intervals

Why we prefer this combination over sermorelin alone:

• The synergistic GHRH + GHRP mechanism produces more reliable IGF-1 elevation
• Once-daily dosing (vs. multiple-daily for some sermorelin protocols)
• Slightly more favorable cost-per-effective-dose in compounded preparations
• Patient experience tends to be slightly better — fewer reports of “not feeling much”

What good response looks like: patients typically report improvements in sleep depth and subjective recovery from training within 3–4 weeks. Body composition changes (modest decrease in fat mass, slight increase in lean mass with appropriate training and nutrition) emerge over 8–12 weeks. IGF-1 typically rises into the upper-normal range for age.

Side effects and contraindications

The side effect profile of CJC-1295 (no DAC) + ipamorelin is generally favorable:

• Transient flushing or warmth shortly after injection, usually resolving within minutes
• Mild head fullness or sinus pressure in the first week
• Vivid dreams when first starting (often welcomed by patients)
• Injection site irritation
• Joint discomfort or water retention if dosing is excessive (signal to reduce dose)
• Tingling in extremities at higher doses

Notably, with the ipamorelin component, cortisol and prolactin elevation is minimal — a major advantage over older GHRPs (GHRP-2, GHRP-6, hexarelin).

Contraindicated in: active malignancy, pregnancy and breastfeeding, pituitary disease, uncontrolled diabetes, active diabetic retinopathy, severe obesity.

What we don’t yet know

Direct comparison of CJC-1295 (no DAC) vs. sermorelin in head-to-head clinical trials is not available. Optimal long-term use patterns — continuous cycling vs. periodic use vs. minimum effective protocols — are not well characterized in formal studies. The relative role of CJC-1295 (no DAC) in adult GH-axis support compared to other interventions (including the more comprehensive lifestyle and sleep interventions that strongly affect endogenous GH) is largely empirical. We present this combination to patients as a well-established but not formally trial-validated tool for supporting age-related GH decline, with realistic expectations about effect sizes and the importance of foundational health behaviors.